%	O
%	O
TITLE	O

HPV	O
Prevalence	B-Incidence_or_Prevalence
and	O
Prognostic	O
Value	O
in	O
a	O
Prospective	O
Cohort	B-Study_Cohort
of	I-Study_Cohort
255	I-Study_Cohort
Patients	I-Study_Cohort
with	I-Study_Cohort
Locally	I-Study_Cohort
Advanced	I-Study_Cohort
HNSCC	I-Study_Cohort
:	O
A	O
Single	O
-	O
Centre	O
Experience	O
.	O

%	O
%	O
ABSTRACT	O

Background	O
.	O

HPV	O
is	O
a	O
positive	O
prognostic	O
factor	O
in	O
HNSCC	O
.	O

We	O
studied	O
the	O
prevalence	B-Incidence_or_Prevalence
and	O
prognostic	O
impact	O
of	O
HPV	O
on	O
survival	O
parameters	O
and	O
treatment	O
toxicity	O
in	O
patients	O
with	O
locally	O
advanced	O
HNSCC	O
treated	O
with	O
concomitant	O
chemoradiation	O
therapy	O
.	O

Methods	O
.	O

Data	O
on	O
efficacy	O
and	O
toxicity	O
were	O
available	O
for	O
560	O
patients	O
.	O

HPV	O
was	O
detected	O
by	O
PCR	B-HPV_Lab_Technique
.	O

Analysis	O
was	O
performed	O
using	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
,	O
Fisher	O
'	O
s	O
test	O
for	O
categorical	O
data	O
,	O
and	O
log	O
-	O
rank	O
statistics	O
for	O
failure	O
times	O
.	O

Results	O
.	O

Median	O
follow	O
-	O
up	O
was	O
4	O
.	O
7	O
years	O
.	O

DNA	O
extraction	O
was	O
successful	O
in	O
255	B-Study_Cohort
cases	I-Study_Cohort
.	O

HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
68	O
.	O
6	O
%	O
,	O
and	O
53	O
.	O
3	O
%	O
for	O
HPV	O
16	O
.	O

For	O
HPV	O
+	O
and	O
HPV	O
-	O
,	O
median	O
LRC	O
was	O
8	O
.	O
9	O
and	O
2	O
.	O
2	O
years	O
(	O
P	O
=	O
0	O
.	O
0002	O
)	O
,	O
median	O
DFS	O
was	O
8	O
.	O
9	O
and	O
2	O
.	O
1	O
years	O
(	O
P	O
=	O
0	O
.	O
0014	O
)	O
,	O
and	O
median	O
OS	O
was	O
8	O
.	O
9	O
and	O
3	O
.	O
1	O
years	O
(	O
P	O
=	O
0	O
.	O
0002	O
)	O
.	O

Survival	O
was	O
different	O
based	O
on	O
HPV	O
genotype	O
,	O
stage	O
,	O
treatment	O
period	O
,	O
and	O
chemotherapy	O
regimen	O
.	O

COX	O
adjusted	O
analysis	O
for	O
T	O
,	O
N	O
,	O
age	O
,	O
and	O
treatment	O
remained	O
significant	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

Conclusions	O
.	O

Oropharyngeal	O
cancer	O
is	O
increasingly	O
linked	O
to	O
HPV	O
.	O

This	O
study	O
confirms	O
that	O
HPV	O
status	O
is	O
associated	O
with	O
improved	O
prognosis	O
among	O
H	O
&	O
N	O
cancer	O
patients	O
receiving	O
CRT	O
and	O
should	O
be	O
a	O
stratification	O
factor	O
for	O
clinical	O
trials	O
including	O
H	O
&	O
N	O
cases	O
.	O

Toxicity	O
of	O
CRT	O
is	O
not	O
modified	O
for	O
the	O
HPV	O
population	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Study	O
Design	O
and	O
Eligibility	O
.	O

The	O
present	O
series	O
com	O
-	O
prises	O
cases	O
from	O
patients	O
participating	O
in	O
an	O
ongoing	O
tumor	O
bank	O
of	O
patients	O
treated	O
for	O
HNSCC	O
at	O
CHUM	O
HoËpital	O
-	O
Notre	O
-	O
Dame	O
since	B-Study_Time
1998	I-Study_Time
.	I-Study_Time

Eligibility	O
criteria	O
included	O
locally	O
advanced	O
HNSCC	O
and	O
treatment	O
with	O
primary	O
chemoradi	O
-	O
ation	O
and	O
with	O
a	O
minimal	O
followup	O
of	O
three	O
years	O
.	O

Surgical	O
treatment	O
preceding	O
chemoradiation	O
was	O
the	O
main	O
exclu	O
-	O
sion	O
criterion	O
.	O

Data	O
were	O
collected	O
prospectively	O
from	O
a	O
regular	O
assessment	O
of	O
outcome	O
variables	O
such	O
as	O
response	O
rates	O
,	O
local	O
or	O
regional	O
recurrences	O
,	O
and	O
survival	O
rates	O
by	O
means	O
of	O
regular	O
clinical	O
and	O
radiological	O
evaluations	O
.	O

All	O
patients	O
had	O
histological	O
confirmation	O
of	O
SCC	O
based	O
on	O
histological	O
features	O
in	O
hematoxylin	O
and	O
eosin	O
-	O
stained	O
tissue	B-HPV_Sample_Type
sections	O
diagnosed	O
by	O
a	O
pathologist	O
experienced	O
in	O
head	O
and	O
neck	O
pathology	O
.	O

Staging	O
was	O
performed	O
according	O
to	O
the	O
TNM	O
classification	O
system	O
from	O
clinical	O
and	O
radiological	O
assessment	O
.	O

Patient	O
Population	O
.	O

All	O
patients	O
with	O
locally	O
advanced	O
HNSCC	O
stage	O
III	O
-	O
IVA	O
-	O
IVB	O
treated	O
with	O
radical	O
radia	O
-	O
tion	O
therapy	O
(	O
min	O
7000cGY	O
standard	O
fractionation	O
or	O
altered	O
fractionation	O
)	O
and	O
concurrent	O
chemotherapy	O
(	O
Cis	O
-	O
platin	O
100	O
mg	O
/	O
m2	O
q3	O
weeks	O
Ã	O
3	O
or	O
Carboplatin	O
70	O
mg	O
/	O
m2	O
d1	O
-	O
4	O

Sample	B-HPV_Sample_Type
Preparation	O
.	O

Three	O
to	O
eight	O
sections	O
of	O
10	O
ðm	O
were	O
obtained	O
from	O
each	O
tumor	O
.	O

To	O
avoid	O
cross	O
-	O
contami	O
-	O
nation	O
during	O
sectioning	O
,	O
disposable	O
microtome	O
blades	O
were	O
used	O
,	O
and	O
the	O
microtome	O
was	O
cleaned	O
after	O
cutting	O
each	O
specimen	B-HPV_Sample_Type
.	O

Biopsy	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
were	O
fixed	O
in	O
10	O
%	O
formalin	O
solution	O
and	O
processed	O
according	O
to	O
conventional	O
methods	O
for	O
paraffin	O
-	O
embedded	O
histological	O
sections	O
for	O
routine	O
diag	O
-	O
nosis	O
.	O

Overview	O
.	O

Prior	O
to	O
HPV	O
detection	O
,	O
samples	B-HPV_Sample_Type
underwent	O
PCR	B-HPV_Lab_Technique
for	O
detection	O
of	O
ð½	O
-	O
globin	O
using	O
the	O
PCO4	O
/	O
GH2O	O
method	O
(	O
268	O
-	O
base	O
pair	O
primers	O
)	O
to	O
control	O
for	O
DNA	O
integrity	O
and	O
for	O
the	O
absence	O
of	O
competing	O
inhibitors	O
.	O

Samples	B-HPV_Sample_Type
were	O
then	O
tested	O
for	O
the	O
presence	O
of	O
HPV	O
DNA	O
using	O
the	O
Roche	O
Linear	O
Array	O
detection	O
method	O
(	O
LA	O
-	O
HPV	O
)	O
(	O
primers	O
450	O
bp	O
)	O
.	O

Samples	B-HPV_Sample_Type
that	O
tested	O
negative	O
for	O
HPV	O
-	O
DNA	O
with	O
the	O
LA	O
-	O
HPV	O
technique	O
were	O
tested	O
using	O
the	O
GP5	B-HPV_Lab_Technique
+	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
GP6	I-HPV_Lab_Technique
+	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
method	I-HPV_Lab_Technique
(	O
primers	O
150	O
bp	O
)	O
.	O

Samples	B-HPV_Sample_Type
that	O
tested	O
negative	O
for	O
both	O
HPV	O
-	O
DNA	O
and	O
ð½	O
-	O
globin	O
with	O
the	O
LA	O
-	O
HPV	O
detection	O
method	O
,	O
and	O
also	O
negative	O
for	O
HPV	O
DNA	O
using	O
the	O
GP5	O
+	O
/	O
GP6	O
+	O
technique	O
,	O
were	O
also	O
tested	O
for	O
the	O
presence	O
of	O
ð½	O
-	O
globin	O
using	O
PCO3	O
/	O
PCO4	O
probes	O
(	O
110	O
bp	O
)	O
to	O
ensure	O
that	O
negative	O
results	O
were	O
not	O
caused	O
by	O
excessive	O
DNA	O
fragmentation	O
due	O
to	O
extended	O
preservation	O
in	O
paraffin	O
.	O

DNA	O
Extraction	O
.	O

Paraffin	O
-	O
embedded	O
samples	B-HPV_Sample_Type
were	O
heated	O
to	O
72âC	O
and	O
washed	O
with	O
xylene	O
for	O
two	O
minutes	O
,	O
four	O
times	O
.	O

The	O
samples	B-HPV_Sample_Type
were	O
then	O
submitted	O
to	O
four	O
one	O
-	O
minute	O
washes	O
with	O
ethanol	O
100	O
%	O
and	O
four	O
one	O
-	O
minute	O
washes	O
with	O
ethanol	O
95	O
%	O
.	O

Remaining	O
tissue	B-HPV_Sample_Type
was	O
then	O
incubated	O
in	O
200	O
ðL	O
lysis	O
buffer	O
(	O
10	O
mM	O
tris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
0	O
,	O
1	O
mM	O
EDTA	O
,	O
pH	O
8	O
.	O
0	O
,	O
and	O
20	O
mM	O
NaCl	O
)	O
containing	O
0	O
.	O
2	O
mg	O
/	O
mL	O
proteinase	O
K	O
for	O
2	O
hours	O
at	O
55âC	O
.	O

The	O
mixture	O
was	O
then	O
heated	O
at	O
96âC	O
for	O
5	O
minutes	O
in	O
order	O
to	O
inactivate	O
proteinase	O
K	O
.	O

Optic	O
density	O
was	O
calculated	O
for	O
the	O
supernate	O
after	O
having	O
centrifuged	O
the	O
mixture	O
at	O
12000	O
G	O
for	O
20	O
minutes	O
.	O

Tubes	O
were	O
then	O
stored	O
at	O

â4âC	O
.	O

PCO4	O
/	O
GH2O	O
PCR	B-HPV_Lab_Technique
.	O

Amplification	O
of	O
a	O
ð½	O
-	O
globin	O
gene	O
fragment	O
was	O
performed	O
by	O
the	O
use	O
of	O
PCO4	O
and	O
GH2O	O
primers	O
to	O
control	O
for	O
target	O
DNA	O
integrity	O
.	O

PCR	B-HPV_Lab_Technique
products	O
were	O
separated	O
by	O
electrophoresis	O
on	O
a	O
2	O
%	O
ethidium	O
-	O
stained	O
agarose	O
gel	O
and	O
visualised	O
on	O
a	O
UV	O
transilluminator	O
.	O

Samples	B-HPV_Sample_Type
generating	O
a	O
visible	O
268	O
-	O
base	O
pair	O
band	O
were	O
judged	O
suitable	O
for	O
detection	O
of	O
HPV	O
DNA	O
using	O
the	O
LA	O
-	O
HPV	O
method	O
[	O
27	O
]	O
,	O
which	O
includes	O
detection	O
of	O
ð½	O
-	O
globin	O
using	O
the	O
PCO4	O
/	O
GH2O	O
method	O
.	O

LA	O
-	O
HPV	O
.	O

As	O
previously	O
described	O
[	O
28	O
]	O
PCR	B-HPV_Lab_Technique
was	O
per	O
-	O
formed	O
in	O
a	O
final	O
reaction	O
volume	O
of	O
100	O
ðL	O
with5	O
ðL	O
of	O
sam	O
-	O
ple	O
material	O
and	O
95	O
ðL	O
of	O
kit	O
working	O
master	O
mix	O
(	O
containing	O
MgCl	O
,	O
KCl	O
,	O
AmpliTaq	O
,	O
gold	O
DNA	O
polymerase	O
(	O
AmpliTaq	O
;	O

+	O
5	O
-	O
FU	O
600	O
mg	O
/	O
m2	O
d1	O
-	O
4	O
q	O
3	O
weeks	O
Ã	O
3	O
or	O
Cisplatin	O
6	O
mg	O
/	O
m2	O
N	O
-	O
glycosylase	O
,	O
dATP	O
,	O

daily	O
or	O
Carboplatin	O
25	O
mg	O
/	O
m2	O
daily	O
)	O
were	O
included	O
in	O
this	O
analysis	O
.	O

Patients	O
were	O
secondarily	O
selected	O
based	O
on	O
the	O
availability	O
of	O
tumor	O
samples	B-HPV_Sample_Type
(	O
cf	O
.	O

Table	O
1	O
)	O
.	O

Perkin	O
-	O
Elmer	O
;	O
Foster	O
City	O
,	O
CA	O
)	O
,	O
uracil	O
-	O

dCTP	O
,	O
dGTP	O
,	O
dUTP	O
,	O
dTTP	O
,	O
and	O
biotinylated	O
PGMY	O
primers	O
and	O
ð½	O
-	O
globin	O
primers	O
GH2O	O
and	O
PCO4	O
)	O
.	O

Test	O
tubes	O
were	O
incubated	O
in	O
a	O
TC	O
9700	O
thermal	O
cycler	O
set	O
at	O
maximum	O
ramp	O

Table	O
1	O
:	O
Patient	O
characteristics	O
according	O
to	O
HPV	O
status	O
.	O

Patient	O
characteristic	O
Number	O
of	O
patients	O

HPV	O
+	O
HPVâ	O
P	O
Total	O

Number	O
of	O
patients	O
175	O
80	O

Age	O
(	O
years	O
)	O

Median	O
55	O
.	O
42	O
59	O
.	O
56	O
t	O
-	O
test	O
ð	O
=	O
0	O
.	O
0086	O
57	O
.	O
00	O

Range	O
25	O
.	O
25â75	O
.	O
03	O
39	O
.	O
64â78	O
.	O
72	O
25	O
.	O
25â78	O
.	O
72	O

T	O
(	O
ð	O
=	O
255	O
)	O

T1	O
36	O
(	O
20	O
.	O
57	O
%	O
)	O
7	O
(	O
8	O
.	O
75	O
%	O
)	O
43	O
(	O
16	O
.	O
86	O
%	O
)	O

T2	O
39	O
(	O
22	O
.	O
29	O
%	O
)	O
17	O
(	O
21	O
.	O
25	O
%	O
)	O
56	O
(	O
21	O
.	O
96	O
%	O
)	O

T3	O
48	O
(	O
27	O
.	O
43	O
%	O
)	O
26	O
(	O
32	O
.	O
50	O
%	O
)	O

Fisher	O
ð	O
=	O
0	O
.	O
0203	O

74	O
(	O
29	O
.	O
02	O
%	O
)	O

N	O

N2	O
0	O
1	O
(	O
1	O
.	O
25	O
%	O
)	O
1	O
(	O
0	O
.	O
39	O
%	O
)	O

T	O

III	O
24	O
(	O
13	O
.	O
71	O
%	O
)	O
11	O
(	O
13	O
.	O
75	O
%	O
)	O

Fisher	O
ð	O
>	O
0	O
.	O
1	O

35	O
(	O
13	O
.	O

73	O
%	O
)	O

Conventional	O
143	O
(	O
82	O
.	O
18	O
%	O
)	O
77	O
(	O
96	O
.	O
25	O
%	O
)	O
Fisher	O
ð	O
=	O
0	O
.	O
0017	O
220	O
(	O
86	O
.	O
28	O
%	O
)	O

âIndicates	O
missing	O
data	O
.	O

speed	O
for	O
2	O
minutes	O
at	O
50âC	O
and	O
9	O
minutes	O
at	O
95âC	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
30	O
seconds	O
at	O
95âC	O
,	O
1	O
minute	O
at	O
55âC	O
,	O
and	O
1	O
minute	O
at	O
72âC	O
,	O
with	O
a	O
final	O
extension	O
at	O
72âC	O
(	O
ramp	O
set	O
at	O
50	O
%	O
)	O
for	O
5	O
minutes	O
.	O

Negative	O
and	O
positive	O
controls	O
were	O
included	O
for	O
each	O
reaction	O
.	O

Amplicons	O
were	O
denatured	O
in	O
0	O
.	O
4	O
N	O
NaOH	O
and	O
hybridise	O
to	O
an	O
immobilised	O
probe	O
array	O
containing	O
probes	O
for	O
37	O
HPV	O
genotypes	O
(	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
Roche	O
Molecular	O
Systems	O
)	O
.	O

Following	O
the	O
hybridization	O
reaction	O
,	O
Linear	O
Array	O
HPV	O
Genotyping	O
Strips	O
were	O
stringently	O
washed	O
to	O
remove	O
unb	O
-	O
ound	O
material	O
,	O
and	O
positive	O
hybridization	O
reactions	O
were	O
detected	O
by	O
streptavidin	O
-	O
horseradish	O
peroxidase	O
-	O
mediated	O
color	O
precipitation	O
on	O
the	O
membrane	O
at	O
the	O
probe	O
line	O
.	O

The	O
probe	O
for	O
detection	O
of	O
HPV	O
52	O
amplicons	O
was	O
a	O
cross	O
-	O
reactive	O
probe	O
that	O
also	O
hybridised	O
with	O
types	O
33	O
,	O
35	O
,	O
and	O
58	O
;	O
samples	B-HPV_Sample_Type
positive	O
with	O
the	O
HPV	O
52	O
probe	O
and	O
containing	O
at	O
least	O
one	O
of	O
those	O
types	O
were	O
thus	O
also	O
tested	O
with	O
a	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
assay	O
specific	O
for	O
HPV	O
52	O
(	O
see	O
below	O
)	O
.	O

Only	O
samples	B-HPV_Sample_Type
positive	O
for	O
HPV	O
52	O
with	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
were	O
considered	O
HPV	O
52	O
positive	O
.	O

Real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
Assay	I-HPV_Lab_Technique
for	O
HPV	O
52	O
.	O

As	O
described	O
previ	O
-	O
ously	O
[	O
28	O
]	O
,	O
20	O
ðL	O
reaction	O
mixtures	O
contained	O
10	O
mM	O
tris	O
-	O
HCl	O
;	O
pH	O
8	O
.	O
0	O
;	O
50	O
mM	O
KCl	O
;	O
a	O
200	O
ðM	O
concentration	O
of	O
(	O
each	O
)	O
ATP	O
,	O
dGTP	O
,	O
and	O
dCTP	O
;	O
400	O
ðM	O
dUTP	O
;	O
0	O
.	O
05	O
ðM	O
of	O
TaqMan	O
probe	O
52	O
-	O
TM	O
(	O
CGTGCAGGGTCCGGGGTC	O
)	O
;	O
0	O
.	O
3	O
pmol	O
each	O
of	O
primers	O
52JA	O
-	O
3	O
(	O
GAACACAGTGTAGCTAACGCACG	O
)	O
and	O
52JA	O
-	O
4	O
(	O
GCATGACGTTACACTTGGGTCA	O
)	O
(	O
targeting	O
the	O
E6	O
gene	O
)	O
;	O
2	O
.	O
0	O
mM	O
MgCl2	O
;	O
and	O
5	O
units	O
of	O
AmpliTaq	O
gold	O
DNA	O
polymerase	O
.	O

Capillaries	O
were	O
placed	O
in	O
a	O
LightCycler	O
system	O
(	O
Roche	O
Molecular	O
Systems	O
;	O
Branchburg	O
,	O
NJ	O
,	O
USA	O
)	O
and	O
amplified	O
at	O
95âC	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
50	O
cycles	O
at	O
95âC	O
for	O
15	O
seconds	O
and	O
60âC	O
for	O
60	O
seconds	O
.	O

Ten	O
copies	O
of	O
an	O
HPV	O
52	O
-	O
expressing	O
plasmid	O
in	O
500	O
ng	O
of	O
cellular	O
DNA	O
served	O
as	O
a	O
weak	O
positive	O
control	O
.	O

GP5	O
+	O
/	O
GP6	O
+	O
PCR	O
.	O

The	O
primers	O
used	O
for	O
HPV	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
were	O
a	O
single	O
pair	O
of	O
consensus	O
GP5	O
+	O
/	O
GP6	O
+	O
(	O
150	O
bp	O
)	O
,	O
as	O
previously	O
described	O
[	O
4	O
]	O
.	O

PCR	B-HPV_Lab_Technique
was	O
carried	O
out	O
in	O
a	O
reac	O
-	O
tion	O
volume	O
of	O
50	O
ðL	O
containing	O
50	O
mM	O
KCl	O
,	O
10	O
mM	O
Tris	O
HCl	O
(	O
pH	O
8	O
.	O
3	O
)	O
,	O
200	O
ðM	O
each	O
deoxynucleoside	O
triphosphate	O
,	O

3	O
.	O
5	O
mM	O
MgCl2	O
,	O
1	O
unit	O
of	O
thermostable	O
DNA	O
polymerase	O
(	O
AmpliTaq	O
;	O
Perkin	O
-	O
Elmer	O
;	O
Foster	O
City	O
,	O
CA	O
)	O
,	O
and	O
50	O
pmol	O
each	O
of	O
the	O
GP5	O
+	O
(	O
5	O
-	O
TTTGTTACTGTGGTAGATACTAC	O
-	O
3	O
)	O
and	O
GP6	O
+	O
(	O
3	O
-	O
CTTATACTAAATGTCAAATAAAAAG	O
-	O
5	O
)	O
primers	O
.	O

Samples	B-HPV_Sample_Type
were	O
denatured	O
for	O
4	O
minutes	O
at	O
94âC	O
and	O
then	O
underwent	O
40	O
cycles	O
of	O
amplification	O
with	O
a	O
PCR	O
processor	O
(	O
PE9600	O
;	O
Perkin	O
-	O
Elmer	O
)	O
.	O

Each	O
cycle	O
consisted	O
of	O
a	O
denaturation	O
step	O
(	O
1	O
minute	O
at	O
94âC	O
)	O
,	O
a	O
primer	O
annealing	O
step	O
(	O
2	O
minutes	O
at	O
40âC	O
)	O
,	O
and	O
a	O
chain	O
elongation	O
step	O
(	O
1	O
.	O
5	O
minute	O
at	O
72âC	O
)	O
.	O

Complete	O
extension	O
of	O
amplified	O
DNA	O
was	O
ensured	O
by	O
prolongation	O
of	O
the	O
final	O
elongation	O
step	O
by	O
4	O
minutes	O
[	O
29	O
]	O
.	O

Negative	O
and	O
positive	O
controls	O
were	O
included	O
for	O
each	O
reaction	O
.	O

PCR	B-HPV_Lab_Technique
products	O
were	O
layered	O
on	O
1	O
.	O
5	O
%	O
agarose	O
gel	O
and	O
trans	O
-	O
ferred	O
onto	O
positively	O
charged	O
nylon	O
membranes	O
(	O
Qiabrane	O
;	O
Westburg	O
)	O
by	O
diffusion	O
blotting	O
in	O
0	O
.	O
5	O
N	O
NaOH	O
-	O
0	O
.	O
6	O
M	O
NaCl	O
.	O

DNA	O
purification	O
by	O
gel	O
extraction	O
was	O
done	O
for	O
samples	B-HPV_Sample_Type
that	O
tested	O
weakly	O
positive	O
.	O

A	O
BLAST	O
search	O
was	O
performed	O
to	O
assign	O
sequences	O
to	O
known	O
HPV	O
types	O
.	O

Gel	O
Extraction	O
Protocol	O
.	O

Gel	O
extraction	O
was	O
performed	O
with	O
the	O
QIAquick	O
Gel	O
Extraction	O
Kit	O
(	O
Qiagen	O
Inc	O
.	O
,	O
Valencia	O
,	O
CA	O
)	O
,	O
according	O
to	O
the	O
supplied	O
protocol	O
.	O

Briefly	O
,	O
DNA	O
frag	O
-	O
ments	O
were	O
excised	O
from	O
the	O
agarose	O
gel	O
with	O
a	O
clean	O
,	O
sharp	O
scalpel	O
.	O

Gel	O
slices	O
were	O
weighed	O
in	O
a	O
colorless	O
tube	O
,	O
and	O
3	O
volumes	O
of	O
buffer	O
QG	O
were	O
added	O
to	O
1	O
volume	O
of	O
gel	O
.	O

Gel	O
was	O
then	O
dissolved	O
via	O
incubation	O
at	O
50âC	O
for	O
10	O
minutes	O
.	O

DNA	O
was	O
bound	O
to	O
the	O
supplied	O
column	O
by	O
centrifugation	O
for	O
1	O
minute	O
followed	O
by	O
discarding	O
of	O
flow	O
-	O
through	O
.	O

0	O
.	O
5	O
of	O
buffer	O
QG	O
was	O
added	O
to	O
each	O
sample	B-HPV_Sample_Type
,	I-HPV_Sample_Type
and	O
flow	O
-	O
through	O
discarded	O
once	O
more	O
after	O
centrifugation	O
for	O
1	O
minute	O
.	O

0	O
.	O
75	O
mL	O
of	O
buffer	O
PE	O
was	O
added	O
to	O
the	O
column	O
and	O
flow	O
-	O
through	O
discarded	O
after	O
centrifugation	O
for	O
further	O
washing	O
.	O

Columns	O
were	O
cen	O
-	O
trifuged	O
again	O
at	O
17	O
,	O
900	O
Ãg	O
and	O
DNA	O
was	O
eluded	O
by	O
addition	O
of	O
50	O
ðL	O
of	O
elution	O
buffer	O
(	O
10	O
mM	O
tris	O
-	O
Cl	O
,	O
pH	O
8	O
.	O
5	O
)	O
to	O
the	O
central	O
membrane	O
of	O
the	O
column	O
followed	O
by	O
centrifugation	O
for	O
1	O
minute	O
.	O

Statistical	O
Analysis	O
.	O

Locoregional	O
control	O
(	O
LRC	O
)	O
was	O
defined	O
as	O
time	O
elapsed	O
between	O
initial	O
diagnosis	O
and	O
devel	O
-	O
opment	O
of	O
recurrent	O
locoregional	O
disease	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
was	O
defined	O
as	O
time	O
elapsed	O
between	O
diagnosis	O
and	O
death	O
from	O
any	O
cause	O
,	O
and	O
disease	O
-	O
free	O
survival	O
was	O
defined	O
as	O
time	O
from	O
initial	O
diagnosis	O
to	O
tumour	O
recurrence	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
Fisherâs	O
test	O
for	O
categorical	O
data	O
and	O
Kaplan	O
-	O
Meierâs	O
curves	O
and	O
log	O
-	O
rank	O
statistics	O
for	O
disease	O
-	O
free	O
survival	O
,	O
overall	O
survival	O
and	O
locoregional	O
control	O
according	O
to	O
HPV	O
status	O
(	O
and	O
HPV	O
genotype	O
)	O
,	O
treatment	O
period	O
,	O
chemotherapy	O
regimen	O
,	O
TNM	O
stage	O
,	O
tumour	O
site	O
,	O
and	O
patient	O
age	O
.	O

Multivariate	O
analysis	O
using	O
COX	O
models	O
was	O
used	O
to	O
adjust	O
for	O
imbalances	O
in	O
the	O
aforementioned	O
prognostic	O
factors	O
between	O
groups	O
.	O

Fisherâs	O
exact	O
test	O
was	O
also	O
performed	O
to	O
determine	O
the	O
difference	O
in	O
acute	O
toxicities	O
(	O
cutaneous	O
toxicity	O
,	O
mucitis	O
,	O
nausea	O
,	O
and	O
vomiting	O
,	O
as	O
well	O
as	O
grade	O
3	O
-	O
4	O
neutropenia	O
)	O
according	O
to	O
HPV	O
status	O
.	O

Smoking	O
status	O
was	O
excluded	O
from	O
our	O
analyses	O
because	O
the	O
data	O
were	O
inconsistently	O
recorded	O
in	O
our	O
database	O
.	O

This	O
protocol	O
was	O
approved	O
by	O
our	O
institutionâs	O
ethics	O
committee	O
.	O

